Particle.news
Download on the App Store
3 ARTICLES
·
3h ago

AstraZeneca Launches U.S. Direct Sales Platform With Farxiga Priced at $182

The move follows White House pressure for lower drug costs.

A U.S. flag stands next to the AstraZeneca logo during a signing event for documents related to a manufacturing site investment at the Meridian International Center in Washington, D.C., July 21, 2025. REUTERS/Umit Bektas/File Photo
Image
Cash-paying patients in the US will be able to buy AstraZeneca's drugs at a step discount of up to 70% off list prices. Credit: Lutsenko_Oleksandr via Shutterstock.com.

Overview

  • Starting October 1, uninsured or underinsured patients can buy Farxiga for $182, with the same price available to Medicare and Medicaid patients on January 1.
  • AstraZeneca will sell Airsupra for $249 and make the FluMist nasal vaccine available through the AstraZeneca Direct site with home delivery.
  • Medicines ordered through the platform ship directly to patients, bypassing pharmacies, insurers and pharmacy benefit managers.
  • It remains unclear how many patients will benefit because coverage patterns and cost-sharing vary widely across commercial and government plans.
  • The rollout joins similar offerings from Bristol Myers Squibb, Pfizer, Eli Lilly and Novo Nordisk under pressure from President Donald Trump, as AstraZeneca highlights a $50 billion U.S. investment plan that includes a new Virginia manufacturing facility.